These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 32031733)

  • 21. Image in clinical medicine. Lentigo maligna.
    Noel B; Kunzle N
    N Engl J Med; 2005 Nov; 353(20):2176. PubMed ID: 16291987
    [No Abstract]   [Full Text] [Related]  

  • 22. Imiquimod for superficial and in situ skin malignancy.
    Drug Ther Bull; 2009 Oct; 47(10):113-6. PubMed ID: 19809085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrence of lentigo maligna and development of invasive melanoma after treatment of lentigo maligna with imiquimod.
    Woodmansee CS; McCall MW
    Dermatol Surg; 2009 Aug; 35(8):1286-9. PubMed ID: 19438661
    [No Abstract]   [Full Text] [Related]  

  • 24. Retrospective review of patients with lentigo maligna treated with topical imiquimod 5% (Aldara®) at a single tertiary UK centre: need for more practical standardised treatment guidelines in the UK.
    Afzal UM; Ghadiri SJ; Sambi P; Muinonen-Martin A; Mitra A
    Clin Exp Dermatol; 2024 Jan; 49(2):163-165. PubMed ID: 37758510
    [No Abstract]   [Full Text] [Related]  

  • 25. Amelanotic lentigo maligna managed with topical imiquimod.
    Lapresta A; García-Almagro D; Sejas AG
    J Dermatol; 2012 May; 39(5):503-5. PubMed ID: 21973079
    [No Abstract]   [Full Text] [Related]  

  • 26. Imiquimod 5% cream in occlusion, for the treatment of lentigo maligna: A new scheme of short cycles and the need for clinical trials.
    Astorino S; Astorre P; Pasquini P; Di Nunno D; Pellegrini F; Paolino G
    Dermatol Ther; 2019 Jan; 32(1):e12757. PubMed ID: 30285299
    [No Abstract]   [Full Text] [Related]  

  • 27. Topical treatment of lentigo maligna melanoma with imiquimod 5% cream.
    Borucki U; Metze D
    Dermatology; 2003; 207(3):326-8. PubMed ID: 14571081
    [No Abstract]   [Full Text] [Related]  

  • 28. Five-year recurrence rate of lentigo maligna after off-label treatment with imiquimod.
    Cliff SH
    Br J Dermatol; 2016 Jan; 174(1):22-3. PubMed ID: 26790655
    [No Abstract]   [Full Text] [Related]  

  • 29. A novel two-stage treatment of lentigo maligna using ablative laser therapy followed by imiquimod.
    de Vries K; Rellum R; Habets JM; Prens EP
    Br J Dermatol; 2013 Jun; 168(6):1362-4. PubMed ID: 23252724
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of Melanocyte Density Counts in Topical Imiquimod-Treated Skin Surrounding Lentigo Maligna vs Control Biopsy Specimens.
    Flores S; Luby NJ; Bowen GM
    JAMA Dermatol; 2018 Apr; 154(4):482-484. PubMed ID: 29453870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Topical Imiquimod for Management of Recurrent Lentigo Maligna Melanoma in Situ.
    Bartenjev MS; Isaković-Vidović S; Bartenjev I
    Acta Dermatovenerol Croat; 2020 Jul; 28(1):34-37. PubMed ID: 32650849
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lentigo maligna managed with topical imiquimod and dermoscopy: report of two cases.
    de Troya-Martín M; Frieyro-Elicegui M; Fúnez Liébana R; Aguilar Bernier M; Fernández-Canedo NI; Blázquez Sánchez N
    Dermatol Surg; 2008 Nov; 34(11):1561-6. PubMed ID: 18798748
    [No Abstract]   [Full Text] [Related]  

  • 33. Imiquimod in the treatment of lentigo maligna.
    Rajpar SF; Marsden JR
    Br J Dermatol; 2006 Oct; 155(4):653-6. PubMed ID: 16965411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Failed treatment of amelanotic lentigo maligna with imiquimod followed by pigment production.
    Martires KJ; Capaldi L; Pattee SF; Maloney ME; Bordeaux JS
    Arch Dermatol; 2010 Sep; 146(9):1047-8. PubMed ID: 20855714
    [No Abstract]   [Full Text] [Related]  

  • 35. Extensive lentigo maligna clearing with topical imiquimod.
    Epstein E
    Arch Dermatol; 2003 Jul; 139(7):944-5. PubMed ID: 12873903
    [No Abstract]   [Full Text] [Related]  

  • 36. Ocular effects of imiquimod with treatment of eyelid melanoma in situ.
    Murchison AP; Washington CV; Soloman AR; Bernardino CR
    Dermatol Surg; 2007 Sep; 33(9):1136-8. PubMed ID: 17760609
    [No Abstract]   [Full Text] [Related]  

  • 37. Rate of recurrence following treatment of lentigo maligna with carbon dioxide laser alone or in combination with imiquimod: Results of a long-term study.
    Kaur A; Javed MU; Venables B; Murison M; Yarrow J
    J Plast Reconstr Aesthet Surg; 2023 Oct; 85():95-97. PubMed ID: 37473646
    [No Abstract]   [Full Text] [Related]  

  • 38. Topical imiquimod treatment of lentigo maligna: clinical and histologic evaluation.
    Kupfer-Bessaguet I; Guillet G; Misery L; Carre JL; Leroy JP; Sassolas B
    J Am Acad Dermatol; 2004 Oct; 51(4):635-9. PubMed ID: 15389205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amelanotic lentigo maligna managed with topical imiquimod as immunotherapy.
    Powell AM; Russell-Jones R
    J Am Acad Dermatol; 2004 May; 50(5):792-6. PubMed ID: 15097969
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients.
    Ly L; Kelly JW; O'Keefe R; Sutton T; Dowling JP; Swain S; Byrne M; Curr N; Wolfe R; Chamberlain A; Haskett M
    Arch Dermatol; 2011 Oct; 147(10):1191-5. PubMed ID: 22006136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.